|
gptkbp:instanceOf
|
gptkb:chemical_compound
gptkb:drug
|
|
gptkbp:approvedBy
|
gptkb:FDA
|
|
gptkbp:ATCCode
|
P01CX02
|
|
gptkbp:CASNumber
|
367-50-2
|
|
gptkbp:combines
|
gptkb:nifurtimox
|
|
gptkbp:contraindication
|
pregnancy
|
|
gptkbp:discoveredBy
|
Charles Bacchi
|
|
gptkbp:form
|
C6H12F2N2O2
|
|
gptkbp:hasInChIKey
|
QXWYNZJAWXJXTE-REOHCLBHSA-N
|
|
gptkbp:hasSMILES
|
C(CN)C(C(=O)O)NCC(F)F
|
|
gptkbp:hasUNII
|
Q9288MUA3K
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
difluoromethylornithine
|
|
gptkbp:includes
|
gptkb:WHO_Model_List_of_Essential_Medicines
|
|
gptkbp:inhibitedBy
|
gptkb:ornithine_decarboxylase
|
|
gptkbp:is_administered_as
|
hydrochloride salt
|
|
gptkbp:is_effective_against
|
gptkb:Trypanosoma_brucei_gambiense
|
|
gptkbp:is_not_effective_against
|
gptkb:Trypanosoma_brucei_rhodesiense
|
|
gptkbp:IUPACName
|
(2R)-2-difluoromethyl-ornithine
|
|
gptkbp:KEGGID
|
D02368
|
|
gptkbp:marketedAs
|
gptkb:Ornidyl
gptkb:Vaniqa
|
|
gptkbp:mechanismOfAction
|
irreversible inhibition of ornithine decarboxylase
|
|
gptkbp:meltingPoint
|
285 °C
|
|
gptkbp:molecularWeight
|
180.17 g/mol
|
|
gptkbp:PubChem_CID
|
2927
3033
CHEMBL1387
CHEBI:42368
|
|
gptkbp:routeOfAdministration
|
oral
intravenous
|
|
gptkbp:sideEffect
|
gptkb:anemia
diarrhea
hearing loss
seizures
leukopenia
gastrointestinal disturbances
|
|
gptkbp:synonym
|
gptkb:eflornithine
gptkb:DFMO
|
|
gptkbp:usedFor
|
treatment of African trypanosomiasis
treatment of hirsutism
|
|
gptkbp:was_developed_in
|
1970s
|
|
gptkbp:bfsParent
|
gptkb:eflornithine
|
|
gptkbp:bfsLayer
|
6
|